Replies to post #205316 on Bioelectronics Corp (BIEL)

[Steve43]

One need only look at the numbers presented as potential users by the Company itself as being in the millions for as you say partially cleared products. Those numbers have been present for nearly three years. The products represented an opportunity to be exploited and put in the public arena of the largest richest Market in the world. Yes two products that. Could have put us into profitability long ago, with the promise of Full Clearance down the road. Deals were available for both products and presented, which would have provided an amazing opportunity for exposure with others beating on the door. We never needed Full Clearance to be profitable. How many large companies started with one product, we had two and expanded those products into other areas? IMO Full Clearance was and is a distraction, covering up for our failure to execute. Many of us would have been out of here long ago with the pps rise that could have been created with just two products. That two product opportunity still sits there. JMHO Have a great day

[pinhigh]

Let's be glad that Mundipharma is at liberty to market the full line of Biel products abroad...including back. If they couldn't market back I'm not sure we would have seen the recent 15000 unit Mundi order. The plantar patch could be a different animal here in the USA though. Now we might be talking about a partner who specializes in foot pain almost exclusively. They might not need full body clearace to commence a deal with Biel. Go Biel$$$

[markjohn62]

I have to disagree with that. Each approved indication has it's own merit. BIEL could be profitable with just the knee or foot indication, not to mention the massive opportunity in RecoveryRX. Dr. Scholls just taking over the foot indication would have given us the legitimacy we are so sorely lacking. The complete lack of any follow through is the issue, not lacking the full clearance for musculoskeletal pain. IMO of course.